-The Times of India MUMBAI: After an embarrassing show in 2009, India has backed out of the Programme for International Student Assessment (PISA) slated for 2015. The programme is a global evaluation process by the Organization for Economic Cooperation and Development (OECD) secretariat that gauges where schoolchildren stand alongside their peers from other countries. This academic Olympics measures the performance of 15 year olds in reading, math and science. Indians were put...

-The Business Standard Angelina Jolie has inadvertently highlighted a key question about patenting Angelina Jolies recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US...

-The Times of India NEW DELHI: A Central government panel has recommended stringent checks for pesticides in fruits and vegetables, including imported ones. Submitting a report before a bench comprising Chief Justice D Murugesan and Justice Jayant Nath on Wednesday, the panel - led by a health ministry official - is for intensive monitoring of pesticide residues on fruits and vegetables sold in Delhi. The experts committee, chaired by Sandhya Kulshrestha, was...

-The Business Standard After the US and Indian authorities, the medicines manufactured by Ranbaxy Laboratories are now under the scanner of hospitals, too. Mumbai's leading Jaslok Hospital has already put up a notice advising its doctors to avoid prescribing Ranbaxy drugs, while some others are reviewing the matter. Medanta Medicity officials say they will soon assess the situation and take a decision. "I have received around a dozen queries from patients recently....

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...